{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T14:34:22Z","timestamp":1793284462196,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100008130","name":"Pusan National University Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s12185-026-04250-x","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T07:16:15Z","timestamp":1785914175000},"page":"680-688","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of the BEBM (bendamustine, etoposide, busulfan, and melphalan) conditioning regimen for autologous stem-cell transplantation in non-Hodgkin lymphoma"],"prefix":"10.1007","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6364-2148","authenticated-orcid":false,"given":"Sang Hun","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9468-8939","authenticated-orcid":false,"given":"Do Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3694-7031","authenticated-orcid":false,"given":"Ho-Jin","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"key":"4250_CR1","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s12185-018-2403-9","volume":"107","author":"KH Yoo","year":"2018","unstructured":"Yoo KH, Lee H, Suh C, CISL. Lymphoma epidemiology in Korea and the real clinical field including the Consortium for Improving Survival of Lymphoma (CISL) trial. Int J Hematol. 2018;107:395\u2013404.","journal-title":"Int J Hematol"},{"key":"4250_CR2","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s11899-017-0382-1","volume":"12","author":"U Zahid","year":"2017","unstructured":"Zahid U, Akbar F, Amaraneni A, Husnain M, Chan O, Riaz IB, et al. A review of autologous stem cell transplantation in lymphoma. Curr Hematol Malig Rep. 2017;12:217\u201326.","journal-title":"Curr Hematol Malig Rep"},{"key":"4250_CR3","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1056\/NEJM198706113162401","volume":"316","author":"T Philip","year":"1987","unstructured":"Philip T, Armitage JO, Spitzer G, Chauvin F, Jagannath S, Cahn JY, et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin\u2019s lymphoma. N Engl J Med. 1987;316:1493\u20138.","journal-title":"N Engl J Med"},{"key":"4250_CR4","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1038\/s41409-018-0378-z","volume":"54","author":"PB Dahi","year":"2019","unstructured":"Dahi PB, Lazarus HM, Sauter CS, Giralt SA. Strategies to improve outcomes of autologous hematopoietic cell transplant in lymphoma. Bone Marrow Transplant. 2019;54:943\u201360.","journal-title":"Bone Marrow Transplant"},{"key":"4250_CR5","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1200\/JCO.1995.13.3.588","volume":"13","author":"W Mills","year":"1995","unstructured":"Mills W, Chopra R, McMillan A, Pearce R, Linch DC, Goldstone AH. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin\u2019s lymphoma. J Clin Oncol. 1995;13:588\u201395.","journal-title":"J Clin Oncol"},{"key":"4250_CR6","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1182\/blood.V77.7.1587.1587","volume":"77","author":"T Philip","year":"1991","unstructured":"Philip T, Chauvin F, Armitage J, Bron D, Hagenbeek A, Biron P, et al. Parma international protocol: pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation. Blood. 1991;77:1587\u201392.","journal-title":"Blood"},{"key":"4250_CR7","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s00277-020-03942-6","volume":"99","author":"DY Kim","year":"2020","unstructured":"Kim DY, Chung JS, Jo JC, Cho SH, Shin HJ. Phase II study of safety and efficacy of BEB (Bendamustine, etoposide, and busulfan) conditioning regimen for autologous stem cell transplantation in non-Hodgkin lymphoma. Ann Hematol. 2020;99:819\u201328.","journal-title":"Ann Hematol"},{"key":"4250_CR8","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.bbmt.2010.07.016","volume":"17","author":"P Kebriaei","year":"2011","unstructured":"Kebriaei P, Madden T, Kazerooni R, Wang X, Thall PF, Ledesma C, et al. Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies. Biol Blood Marrow Transplant. 2011;17:412\u201320.","journal-title":"Biol Blood Marrow Transplant"},{"key":"4250_CR9","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.bbmt.2012.08.011","volume":"19","author":"UD Bayraktar","year":"2013","unstructured":"Bayraktar UD, Bashir Q, Qazilbash M, Champlin RE, Ciurea SO. Fifty years of melphalan use in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013;19:344\u201356.","journal-title":"Biol Blood Marrow Transplant"},{"key":"4250_CR10","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","volume":"359","author":"N Schmitz","year":"2002","unstructured":"Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: a randomised trial. Lancet. 2002;359:2065\u201371.","journal-title":"Lancet"},{"key":"4250_CR11","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/sj.bmt.1701101","volume":"21","author":"CH Weaver","year":"1998","unstructured":"Weaver CH, Schwartzberg L, Rhinehart S, West J, Zhen B, West WH, et al. High-dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin\u2019s lymphoma. Bone Marrow Transplant. 1998;21:383\u20139.","journal-title":"Bone Marrow Transplant"},{"key":"4250_CR12","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/sj.bmt.1705841","volume":"40","author":"JG Kim","year":"2007","unstructured":"Kim JG, Sohn SK, Chae YS, Yang DH, Lee JJ, Kim HJ, et al. Multicenter study of intravenous busulfan, cyclophosphamide, and etoposide (i.v. Bu\/Cy\/E) as conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin\u2019s lymphoma. Bone Marrow Transplant. 2007;40:919\u201324.","journal-title":"Bone Marrow Transplant"},{"key":"4250_CR13","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.bbmt.2004.05.010","volume":"10","author":"CB Williams","year":"2004","unstructured":"Williams CB, Day SD, Reed MD, Copelan EA, Bechtel T, Leather HL, et al. Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies. Biol Blood Marrow Transplant. 2004;10:614\u201323.","journal-title":"Biol Blood Marrow Transplant"},{"key":"4250_CR14","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1158\/1078-0432.CCR-07-1061","volume":"14","author":"LM Leoni","year":"2008","unstructured":"Leoni LM, Bailey B, Reifert J, Bendall HH, Zeller RW, Corbeil J, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res. 2008;14:309\u201317.","journal-title":"Clin Cancer Res"},{"key":"4250_CR15","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1007\/s00280-015-2727-6","volume":"75","author":"M Darwish","year":"2015","unstructured":"Darwish M, Bond M, Hellriegel E, Robertson P Jr, Chovan JP. Pharmacokinetic and pharmacodynamic profile of Bendamustine and its metabolites. Cancer Chemother Pharmacol. 2015;75:1143\u201354.","journal-title":"Cancer Chemother Pharmacol"},{"key":"4250_CR16","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1182\/blood.V81.2.319.319","volume":"81","author":"NJ Chao","year":"1993","unstructured":"Chao NJ, Stein AS, Long GD, Negrin RS, Amylon MD, Wong RM, et al. Busulfan\/etoposide\u2014initial experience with a new preparatory regimen for autologous bone marrow transplantation in patients with acute nonlymphoblastic leukemia. Blood. 1993;81:319\u201323.","journal-title":"Blood"},{"issue":"Suppl 1","key":"4250_CR17","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1038\/leusup.2013.3","volume":"2","author":"S Giralt","year":"2013","unstructured":"Giralt S, Bensinger W. Stem cell transplantation for multiple myeloma: current and future status. Leuk Suppl. 2013;2(Suppl 1):S10\u20134.","journal-title":"Leuk Suppl"},{"key":"4250_CR18","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1200\/JCO.1988.6.11.1768","volume":"6","author":"G Sarosy","year":"1988","unstructured":"Sarosy G, Leyland-Jones B, Soochan P, Cheson BD. The systemic administration of intravenous melphalan. J Clin Oncol. 1988;6:1768\u201382.","journal-title":"J Clin Oncol"},{"key":"4250_CR19","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s00277-016-2900-y","volume":"96","author":"S Gilli","year":"2017","unstructured":"Gilli S, Novak U, Taleghani BM, Baerlocher GM, Leibundgut K, Banz Y, et al. BeEAM conditioning with Bendamustine-replacing BCNU before autologous transplantation is safe and effective in lymphoma patients. Ann Hematol. 2017;96:421\u20139.","journal-title":"Ann Hematol"},{"key":"4250_CR20","doi-asserted-by":"publisher","first-page":"641","DOI":"10.3109\/10428191003611428","volume":"51","author":"AP Grigg","year":"2010","unstructured":"Grigg AP, Stone J, Milner AD, Schwarer AP, Wolf M, Prince HM, et al. Phase II study of autologous stem cell transplant using busulfan-melphalan chemotherapy-only conditioning followed by interferon for relapsed poor prognosis follicular non-Hodgkin lymphoma. Leuk Lymphoma. 2010;51:641\u20139.","journal-title":"Leuk Lymphoma"},{"key":"4250_CR21","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00277-007-0360-0","volume":"87","author":"JC Jo","year":"2008","unstructured":"Jo JC, Kang BW, Jang G, Sym SJ, Lee SS, Koo JE, et al. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin\u2019s lymphoma patients: comparative analysis of efficacy and toxicity. Ann Hematol. 2008;87:43\u20138.","journal-title":"Ann Hematol"},{"key":"4250_CR22","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.1182\/blood-2011-04-351924","volume":"118","author":"G Visani","year":"2011","unstructured":"Visani G, Malerba L, Stefani PM, Capria S, Galieni P, Gaudio F, et al. BeEAM (Bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant\/relapsed lymphoma patients. Blood. 2011;118:3419\u201325.","journal-title":"Blood"},{"key":"4250_CR23","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.3109\/10428194.2014.882504","volume":"55","author":"HJ Shin","year":"2014","unstructured":"Shin HJ, Lee WS, Lee HS, Kim H, Lee GW, Song MK, et al. Busulfan-containing conditioning regimens are optimal preparative regimens for autologous stem cell transplant in patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2014;55:2490\u20136.","journal-title":"Leuk Lymphoma"},{"key":"4250_CR24","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1634\/theoncologist.2009-0162","volume":"14","author":"AJ Moskowitz","year":"2009","unstructured":"Moskowitz AJ, Moskowitz CH. Controversies in the treatment of lymphoma with autologous transplantation. Oncologist. 2009;14:921\u20139.","journal-title":"Oncologist"},{"key":"4250_CR25","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1056\/NEJMoa1301077","volume":"369","author":"PJ Stiff","year":"2013","unstructured":"Stiff PJ, Unger JM, Cook JR, Constine LS, Couban S, Stewart DA, et al. Autologous transplantation as consolidation for aggressive non-Hodgkin\u2019s lymphoma. N Engl J Med. 2013;369:1681\u201390.","journal-title":"N Engl J Med"},{"key":"4250_CR26","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.3324\/haematol.2021.279426","volume":"107","author":"AM Garc\u00eda-Sancho","year":"2022","unstructured":"Garc\u00eda-Sancho AM, Bellei M, L\u00f3pez-Parra M, Gritti G, Cort\u00e9s M, Novelli S, et al. Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO\/FIL study. Haematologica. 2022;107:2675\u201384.","journal-title":"Haematologica"},{"key":"4250_CR27","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s13045-018-0670-9","volume":"11","author":"M Alcantara","year":"2018","unstructured":"Alcantara M, Tesio M, June CH, Houot R. CAR T-cells for T-cell malignancies: challenges in targeting the shared antigens. J Hematol Oncol. 2018;11:124.","journal-title":"J Hematol Oncol"},{"key":"4250_CR28","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.hoc.2008.07.010","volume":"22","author":"JM Vose","year":"2008","unstructured":"Vose JM. Peripheral T-cell non-Hodgkin\u2019s lymphoma. Hematol Oncol Clin North Am. 2008;22:997\u20131005.","journal-title":"Hematol Oncol Clin North Am"},{"key":"4250_CR29","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1200\/JOP.18.00511","volume":"15","author":"AJ Moskowitz","year":"2019","unstructured":"Moskowitz AJ. Practical treatment approach for angioimmunoblastic T-cell lymphoma. J Oncol Pract. 2019;15:137\u201343.","journal-title":"J Oncol Pract"},{"key":"4250_CR30","doi-asserted-by":"publisher","DOI":"10.1177\/09636897231179364","volume":"32","author":"R Wu","year":"2023","unstructured":"Wu R, Ma L. BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) versus BEAM (Carmustine, Etoposide, Cytarabine, Melphalan) as conditioning regimen before autologous haematopoietic cell transplantation: a systematic review and meta-analysis. Cell Transplant. 2023;32:9636897231179364. https:\/\/doi.org\/10.1177\/09636897231179364.","journal-title":"Cell Transplant"},{"issue":"6","key":"4250_CR31","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/ajh.25077","volume":"93","author":"SP Chantepie","year":"2018","unstructured":"Chantepie SP, Garciaz S, Tchernonog E, Peyrade F, Larcher MV, Diouf M, et al. Bendamustine-based conditioning prior to autologous stem cell transplantation (ASCT): results of a French multicenter study of 474 patients from Lymphoma Study Association (LYSA) centers. Am J Hematol. 2018;93(6):729\u201335.","journal-title":"Am J Hematol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04250-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-026-04250-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-026-04250-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T13:53:17Z","timestamp":1793281997000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-026-04250-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["4250"],"URL":"https:\/\/doi.org\/10.1007\/s12185-026-04250-x","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]},"assertion":[{"value":"24 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest in preparing this article.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}